Cervical cancer incidence in a prevaccine era in the United States, 1998-2002

Obstetrics and Gynecology

Volumn 109, Issue 2 PART 1, 2007, Pages 360-370

  Saraiya, Mona ^a   Ahmed, Faruque ^b   Krishnan, Sheila ^b   Richards, Thomas B ^b   Unger, Elizabeth R ^b   Lawson, Herschel W ^b  

^a Division of Violence Prevention   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

ADENOCARCINOMA; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CANCER SCREENING; ETHNICITY; FEMALE; GEOGRAPHY; HISPANIC; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RACE DIFFERENCE; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; UTERINE CERVIX CANCER;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CARCINOMA; CHILD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; INCIDENCE; INFANT; MIDDLE AGED; NEOPLASM INVASIVENESS; OCEANIC ANCESTRY GROUP; SEER PROGRAM; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 33846659423     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000254165.92653.e8     Document Type: Article

References (30)

1. Singh GK, Miller BA, Hankey BF, Edwards BK. Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage, and survival, 1975-2000. Cancer 2004;101:1051-7.
2. Yabroff KR, Lawrence WF, King JC, Mangan P, Washington KS, Yi B, et al. Geographic disparities in cervical cancer mortality: what are the roles of risk factor prevalence, screening, and use of recommended treatment? J Rural Health 2005;21:149-57.
3. Freeman H, Wingrove B. Excess cervical cancer mortality: a marker for low access to health care in poor communities. NIH Report No. 05-5282. Rockville (MD): National Cancer Institute, Center to Reduce Cancer Health Disparities; 2005.
4. Ries LAG, Harkins D, Krapcho M, Mariotta A, Miller BA, Feuer EJ, et al. National Cancer Institute. SEER cancer statistics review, 1975-2003. Based on November 2005 SEER data submission, posted to the SEER Web site, 2006. Available at: http://seer.cancer.gov/csr/1975_2003/. Retrieved December 3, 2006.
5. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
6. U.S. Cancer Statistics Working Group. United States cancer statistics: 1999-2002 incidence and mortality Web-based report version. Available at: http://www.cdc.gov/cancer/npcr/publications/. Retrieved December 13, 2006. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2005.
7. Wingo PA, Jamison PM, Hiatt RA, Weir HK, Gargiullo PM, Hutton M, et al. Building the infrastructure for nationwide cancer surveillance and control - a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control 2003;14:175-93.
8. World Health Organization. International classification of disease for oncology. 3rd ed. Geneva (Switzerland): World Health Organization; 2003.
9. National Cancer Institute. SEER Site Recode ICD O-3 (1/27/2003). Surveillance, Epidemiology, and End Results (SEER) Program, 2003. Available at: http://seer.cancer.gov/siterecode/icdo3_d01272003/. Retrieved October 27, 2006.
10. Berg JW. Morphological classification of human cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention. 2nd ed. New York (NY): Oxford University Press; 1996. p. 28-44.
11. Surveillance, Epidemiology and End Results Program. Summary staging guide for the cancer Surveillance, Epidemiology, and End Results (SEER) Program. Bethesda (MD): National Institutes of Health, National Cancer Institute; 1977.
12. Surveillance, Epidemiology and End Results Program. Summary staging manual 2000. Bethesda (MD): National Institutes of Health, National Cancer Institute; 2005.
13. Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994 Jan;10:31-46.
14. Fay MP, Feuer EJ. Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med 1997;16:791-801.
15. Fay MP. Approximate confidence intervals for rate ratios from directly standardized rates with sparse data. Commun Stat Theory Methods 1999;28:2141-60.
16. Wang SS, Sherman ME, Hildesheim A, Lacey JV Jr, Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 2004;100:1035-44.
17. Chan PG, Sung HY, Sawaya GF. Changes in cervical cancer incidence after three decades of screening US women less than 30 years old. Obstet Gynecol 2003;102:765-73.
18. Ahluwalia IB, Mack KA, Murphy W, Mokdad AH, Bales VS. State-specific prevalence of selected chronic disease-related characteristics - Behavioral Risk Factor Surveillance System, 2001. MMWR Surveill Summ 2003;52:1-80.
19. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer 2003;97:1528-40.
20. Seeff LC, McKenna MT. Cervical cancer mortality among foreign-born women living in the United States, 1985 to 1996. Cancer Detect Prev 2003;27:203-8.
21. Kwong SL, Chen MS Jr, Snipes KP, Bal DG, Wright WE. Asian subgroups and cancer incidence and mortality rates in California. Cancer 2005;104 suppl: 2975-81.
22. Mills PK, Yang RC, Riordan D. Cancer incidence in the Hmong in California, 1988-2000. Cancer 2005;104 suppl:2969-74.
23. Schorge JO, Lea JS, Garner EO, Duska LR, Miller DS, Coleman RL. Cervical adenocarcinoma survival among Hispanic and white women: a multicenter cohort study. Am J Obstet Gynecol 2003;188:640-4.
24. Patel DA, Barnholtz-Sloan JS, Patel MK, Malone JM Jr, Chuba PJ, Schwartz K. A population-based study of racial and ethnic differences in survival among women with invasive cervical cancer: analysis of Surveillance, Epidemiology, and End Results data. Gynecol Oncol 2005;97:550-8.
25. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006;119:2677-84.
26. Hildesheim A, Berrington de Gonzalez A. Etiology and prevention of cervical adenocarcinomas. J Natl Cancer Inst 2006;98:292-3.
27. Kurman R, Norris HJ, Wilkinson EJ. Tumors of the cervix, vagina, and vulva. atlas of tumor pathology. Washington (DC): Armed Forces Institute of Pathology; 1992.
28. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98:303-15.
29. Chandra A, Martinez GM, Mosher WB, Abma JC, Jones J. Fertility, family planning, and reproductive health among US women: data from the 2002 National Survey of Family Growth. Vital Health Stat 23 (25). 2005.
30. Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer 2000;88:2283-9.